Literature DB >> 25034069

The MOGE(S) classification of cardiomyopathy for clinicians.

Eloisa Arbustini1, Navneet Narula2, Luigi Tavazzi3, Alessandra Serio1, Maurizia Grasso1, Valentina Favalli1, Riccardo Bellazzi4, Jamil A Tajik5, Robert O Bonow, Robert D Bonow6, Valentin Fuster7, Jagat Narula8.   

Abstract

Most cardiomyopathies are familial diseases. Cascade family screening identifies asymptomatic patients and family members with early traits of disease. The inheritance is autosomal dominant in a majority of cases, and recessive, X-linked, or matrilinear in the remaining. For the last 50 years, cardiomyopathy classifications have been based on the morphofunctional phenotypes, allowing cardiologists to conveniently group them in broad descriptive categories. However, the phenotype may not always conform to the genetic characteristics, may not allow risk stratification, and may not provide pre-clinical diagnoses in the family members. Because genetic testing is now increasingly becoming a part of clinical work-up, and based on the genetic heterogeneity, numerous new names are being coined for the description of cardiomyopathies associated with mutations in different genes; a comprehensive nosology is needed that could inform the clinical phenotype and involvement of organs other than the heart, as well as the genotype and the mode of inheritance. The recently proposed MOGE(S) nosology system embodies all of these characteristics, and describes the morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E) including genetic defect or underlying disease/substrate, and the functional status (S) of the disease using both the American College of Cardiology/American Heart Association stage and New York Heart Association functional class. The proposed nomenclature is supported by a web-assisted application and assists in the description of cardiomyopathy in symptomatic or asymptomatic patients and family members in the context of genetic testing. It is expected that such a nomenclature would help group cardiomyopathies on their etiological basis, describe complex genetics, and create collaborative registries.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiomyopathy; classification; genetics

Mesh:

Year:  2014        PMID: 25034069     DOI: 10.1016/j.jacc.2014.05.027

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  31 in total

1.  Hypertrophic obstructive cardiomyopathy and mitral regurgitation in Libman-Sacks endocarditis.

Authors:  Go Yamashita; Naoki Kanemitsu; Yasuaki Nakashima; Takehiko Matsuo; Takeichiro Nakane; Masanori Honda; Hitoshi Okabayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-12-05

Review 2.  [Genetic testing to prevent sudden cardiac death].

Authors:  B Stallmeyer; S Dittmann; E Schulze-Bahr
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

3.  Cofilin-2 phosphorylation and sequestration in myocardial aggregates: novel pathogenetic mechanisms for idiopathic dilated cardiomyopathy.

Authors:  Khaushik Subramanian; Davide Gianni; Cristina Balla; Gabriele Egidy Assenza; Mugdha Joshi; Marc J Semigran; Thomas E Macgillivray; Jennifer E Van Eyk; Giulio Agnetti; Nazareno Paolocci; James R Bamburg; Pankaj B Agrawal; Federica Del Monte
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

Review 4.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 5.  Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy.

Authors:  Miriam Shanks; Victoria Delgado; Jeroen J Bax
Journal:  J Atr Fibrillation       Date:  2016-02-29

6.  Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy.

Authors:  Keisuke Inui; Kuniya Asai; Masaki Tachi; Aya Yoshinaga; Yuki Izumi; Yoshiaki Kubota; Koji Murai; Yayoi Tetsuou Tsukada; Yasuo Amano; Shinichiro Kumita; Wataru Shimizu
Journal:  Heart Vessels       Date:  2018-03-20       Impact factor: 2.037

Review 7.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 8.  Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy.

Authors:  Amit R Patel; Christopher M Kramer
Journal:  JACC Cardiovasc Imaging       Date:  2017-10

9.  Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry.

Authors:  Katarzyna Mizia-Stec; Philippe Charron; Juan Ramon Gimeno Blanes; Perry Elliott; Juan Pablo Kaski; Aldo P Maggioni; Luigi Tavazzi; Michał Tendera; Stephan B Felix; Fernando Dominguez; Natalia Ojrzynska; Maria-Angela Losi; Giuseppe Limongelli; Roberto Barriales-Villa; Petar M Seferovic; Elena Biagini; Maciej Wybraniec; Cecile Laroche; Alida L P Caforio
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

10.  Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy.

Authors:  Brian P Halliday; Ali Vazir; Ruth Owen; John Gregson; Rebecca Wassall; Amrit S Lota; Zohya Khalique; Upasana Tayal; Richard E Jones; Daniel Hammersley; Antonis Pantazis; A John Baksi; Stuart Rosen; Dudley J Pennell; Martin R Cowie; John G F Cleland; Sanjay K Prasad
Journal:  JACC Heart Fail       Date:  2021-06-09       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.